Investors

Press Releases

Press Releases

June 3, 2020
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Allakos Inc.
May 11, 2020
REDWOOD CITY, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020.
March 24, 2020
Phase 3 study of antolimab for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis) Phase 2/3 study of antolimab for the treatment of eosinophilic esophagitis Phase 1 study of subcutaneously administered antolimab in healthy

Data Provided by Refinitiv. Minimum 15 minutes delayed.